BMO Downgrades ResMed (RMD) to Market Perform; $41 PT
More News related to RMD
- ResMed Inc. to Present at Upcoming Conferences in June
- ResMed (RMD) Reports Q1 EPS of $0.52, Beats by 6c
- ResMed Inc. Announces Record Financial Results for the Quarter and Nine Months Ended March 31, 2009
- ResMed Inc. to Present at Upcoming Healthcare Conferences in May
- Wachovia Downgrades ResMed (RMD) to Market Perform
BMO Capital downgrades ResMed (NYSE: RMD) from Outperform to Market Perform. The firm has a $41 price target on the stock.
ResMed, Inc. engages in the design, manufacture, and marketing of equipment for the diagnosis and treatment of -disordered breathing, including obstructive sleep apnea, and other respiratory disorders that occur during sleep.
Related Categories
DowngradesStocks Mentioned
-15.28Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
